2American Diabetes Association. Standards of medical care in diabetes-2011 [ J ]. Diabetes Care, 2011,34 (Suppl 1):Sll-$61. 被引量：1
3BARRATF J, TOPHAM P. Urine proteomics: the present and future of measuring urinary protein components in disease [ J ]. CMAJ, 2007, 177 ( 4 ) : 361-368. 被引量：1
4BOLIGNANO D, LACQUANITI A, COPPOLINO G,et al. Neutrophil gelatinase-associated lipocalin as an early biomarker of nephropathy in diabetic patients [ J ]. Kidney Blood Press Res,2009,32 (2): 91-98. 被引量：1
5MORESCO RN, SANGOI MB, DE CARVALHO JA, et al. Diabetic nephropathy: traditional to proteomic markers[ J]. Clin Chim Acta,2013 ,d21:17-30. 被引量：1
6KIM SS, SONG SH, KIM I J, et al. Clinical implication of urinary tubular markers in the early stage of nephropathy with type 2 diabetic patients [ J ]. Diabetes Res Clin Pract,2012,97 (2) :251-257. 被引量：1
7KIM SS, SONG SH, KIM IJ, et al. Urinary cystatin C and tubular proteinuria predict progression of diabetic nephropathy [ J ]. Diabetes Care, 2013,36 (3) :656-661. 被引量：1
8HAN WK, WAGENER G, ZHU Y, et al. Urinary biomarkers in the early detection of acute kidney injury after cardiac surgery [ J ]. Clin J Am Soc Nephro1,2009,4 ( 5 ) :873-882. 被引量：1
9NIELSEN SE, REINHARD H, ZDUNEK D, et al. Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients [ J ]. Diabetes Res Clin Pract, 2012,97 ( 1 ) :71-76. 被引量：1
10YANG J, GOETZ D, LI JY, et al. An iron delivery pathway mediated by a lipocalin[ J]. Mol Ce11,2002, 10(5) :1045-1056. 被引量：1
